References
[1] Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castanos C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O’Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F: The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020, 8:65-124.
[2] Elborn JS: Cystic fibrosis. Lancet 2016, 388:2519-31.
[3] Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-51.
[4] Stoltz DA, Meyerholz DK, Welsh MJ: Origins of cystic fibrosis lung disease. N Engl J Med 2015, 372:1574-5.
[5] Tracy MC, Moss RB: The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol 2018, 53:S75-S85.
[6] Janahi IA, Rehman A, Al-Naimi AR: Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ann Thorac Med 2017, 12:74-82.
[7] Amin R, Dupuis A, Aaron SD, Ratjen F: The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010, 137:171-6.
[8] Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW: Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013, 132:560-6 e10.
[9] King J, Brunel SF, Warris A: Aspergillus infections in cystic fibrosis. J Infect 2016, 72 Suppl:S50-5.
[10] Antunes J, Fernandes A, Borrego LM, Leiria-Pinto P, Cavaco J: Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr) 2010, 38:278-84.
[11] Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP: Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010, 9:110-6.
[12] de Vrankrijker AM, van der Ent CK, van Berkhout FT, Stellato RK, Willems RJ, Bonten MJ, Wolfs TF: Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect 2011, 17:1381-6.
[13] Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999, 179:1190-6.
[14] Keown K, Reid A, Moore JE, Taggart CC, Downey DG: Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis. Eur Respir Rev 2020, 29.
[15] Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR: Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017, 181S:S4-S15 e1.
[16] Saiman L, Siegel J, Cystic Fibrosis F: Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003, 24:S6-52.
[17] Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM, Network GIotCFFTD: Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015, 60:703-12.
[18] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
[19] Kent BD, Lane SJ, van Beek EJ, Dodd JD, Costello RW, Tiddens HA: Asthma and cystic fibrosis: a tangled web. Pediatr Pulmonol 2014, 49:205-13.
[20] Nielsen AO, Qayum S, Bouchelouche PN, Laursen LC, Dahl R, Dahl M: Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis. J Cyst Fibros 2016, 15:563-7.
[21] Nguyen LD, Viscogliosi E, Delhaes L: The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015, 6:89.
[22] Kaur S, Singh S: Biofilm formation by Aspergillus fumigatus. Med Mycol 2014, 52:2-9.
[23] Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, Ramage G: Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 2010, 313:96-102.
[24] Akil N, Muhlebach MS: Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. Pediatr Pulmonol 2018, 53:S64-S74.
[25] Cabaret O, Bonnal C, Canoui-Poitrine F, Emirian A, Bizouard G, Levesque E, Maitre B, Fihman V, Decousser JW, Botterel F: Concomitant presence of Aspergillus fumigatus and Stenotrophomonas maltophilia in the respiratory tract: a new risk for patients with liver disease? J Med Microbiol 2016, 65:414-9.
[26] Foundation CF: 2019 Patient Registry Annual Data Report. 2020.
[27] Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP: Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000, 19:53-6.
[28] Chotirmall SH, McElvaney NG: Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol 2014, 52:161-73.
[29] Coron N, Pihet M, Frealle E, Lemeille Y, Pinel C, Pelloux H, Gargala G, Favennec L, Accoceberry I, Durand-Joly I, Dalle F, Huet F, Fanton A, Boldron A, Loeuille GA, Domblides P, Coltey B, Pin I, Llerena C, Troussier F, Person C, Marguet C, Wizla N, Thumerelle C, Turck D, Bui S, Fayon M, Duhamel A, Prevotat A, Wallaert B, Leroy S, Bouchara JP, Delhaes L: Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study. Mycopathologia 2018, 183:101-17.